Shorter Time Interval Treatments for Early Medical Abortions: a Mixed Methods Research Approach by Dr

Total Page:16

File Type:pdf, Size:1020Kb

Shorter Time Interval Treatments for Early Medical Abortions: a Mixed Methods Research Approach by Dr Shorter time interval treatments for Early Medical Abortions: A Mixed Methods Research Approach By Dr. Sheethal Madari A thesis submitted to the University of Birmingham for the degree of DOCTOR OF MEDICINE Doctor of Medicine School of Clinical & Experimental Medicine University of Birmingham May 2017 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. Abstract Purpose This dissertation focuses at assessing the efficacy of shorter time intervals in the treatment of medical abortions along with the use of various follow up methods. Methods This initial part of dissertation was carried out as an extensive study of literature, followed by observational study on shorter time intervals and follow up methods for the feasibility of the study. The main dissertation met its research aims through an RCT of 121 women comparing shorter to standard time intervals and assessing the various follow up methods at the end of 2 weeks. The qualitative component of the study was achieved by conducting in-depth interviews of women undergoing medical abortion on various aspects of medical abortions with emphasis on shorter time intervals and follow up. Findings This research produced a number of key findings: the RCT showed that both treatments have equal efficacy and acceptability with minor differences in their side effects however the sample size was small to generalise the findings; the follow up methods showed varied responses with preference to confirmatory investigations at 2 weeks follow up. Conclusions The main conclusions drawn from this research were that shorter time intervals can be offered as an alternative to standard treatment intervals in well informed women, however a larger RCT is needed. In order to provide these treatments as outpatient robust follow up methods will need to be incorporated into the abortion services. Acknowledgements I am truly indebted and thankful to my supervisors Professor Janesh Gupta and Professor Sheila Greenfield for the support and guidance they showed me throughout my dissertation writing. I am sure it would not have been possible without their help. I would like to thank the staff at the Calthorpe clinic for helping me in successfully carrying out the research at their clinic. I am obliged to the Wilma Arnold (medical secretary at Birmingham Women’s Hospital) and Katherine Lapsworth (medical secretary at Calthorpe Clinic) for their assistance in transcribing the interviews, without whose help the qualitative study would not have been possible. I am also grateful to Derek Yates (Librarian at Birmingham Women’s Hospital), Lee Middleton (Senior Medical Statistician at the Birmingham Clinical Trials Unit) and Melanie Calvert (Professor of Outcomes Methodology at Institute of Applied Health Research, University of Birmingham) for their advice. I am grateful to Professor Christian Fiala and Dr Helena von Hertzen for their time and input as external advisors. I would like to sincerely extend my gratitude to all the women who took part in the study, who made the study possible. Finally, I would like to thank my mother who boost my morale and kept me going to complete the thesis. TABLE OF CONTENTS Forward: Why research Early Medical Abortions? 1 Introduction: Structure and overview of the thesis 3 Part 1: LITERATURE REVIEW: WHAT DO WE KNOW ABOUT MEDICAL ABORTIONS 1.1 History of Medical Abortion treatments 7 1.2 Pharmacodynamics of mifepristone 10 1.3 Pharmacodynamics of misoprostol 13 1.4 Clinical effects of mifepristone and misoprostol based on their Pharmacokinetics 16 1.5 Overview of Currently Available Medical Abortion Methods 20 1.6 Literature review on methods of follow up following treatments for Early Medical Abortions 22 1.6.1 Monitoring medical abortion 22 1.6.2 Methods 24 1.6.3 Results 25 1.6.3.1 Clinical assessment 25 1.6.3.2 Urine hCG 26 1.6.3.3 Serum βhCG 27 1.6.3.4 Combination tests: USS and endometrial thickness 28 1.6.3.5 Ultrasonography 29 1.6.4 Discussion 29 1.6.5 Conclusion 31 1.7 Literature Review on qualitative aspects of Abortions 33 1.7.1 Literature search and methodology 33 1.7.2 Results 34 1.7.2.1 Attitudes towards Abortions 34 1.7.2.2 Process of decision making 37 1.7.2.3 Surgical vs Medical abortion: Acceptability 39 1.7.2.4 Characteristics of patients 43 1.7.2.5 Home Management 45 1.7.2.6 Over the counter treatments 48 1.7.2.7 Views on very early abortions 48 1.7.2.8 Psychological aspects 50 1.7.2.9 Long term consequences of medical abortions 51 1.7.3 Overall summary of findings 52 PART 2: EVIDENCE ON EFFICACY OF VARIOUS TIME INTERVALS- SYSTEMATIC REVIEW AND META-ANALYSIS 2.1 Introduction 56 2.2 Methodology 57 2.2.1 Search and Selection 57 2.2.2 Study population and eligibility criteria 57 2.2.3 Assessment of methodological quality and data extraction 58 2.2.4 Data analysis 58 2.3 Results 59 2.3.1 Selected studies 59 2.3.2 Methodological quality, Description of studies and Characteristics 59 2.3.3 Effect of time interval 61 2.3.3.1 24 hrs versus 36-48 hrs or more 62 2.3.3.2 < 24 hrs versus ≥ 24 hrs 62 2.3.4 Effect of number of doses prostaglandin analogues 63 2.3.5 Effect of gestational age 64 2.3.6 Acceptability 64 2.3.7 Bleeding 66 2.3.8 Pain 67 2.3.9 Induction to abortion interval 68 2.3.10 Complications 68 2.3.11 Effect of Other Regimen Factors that Effect Efficacy 69 2.3.12 Effect of Study Characteristics 70 2.4 Discussion 70 2.5 Overall summary of findings 72 PART 3: CURRENT PRACTICE- OBSERVATIONAL STUDY 3.1 Retrospective Audit on Early Medical Abortions at various time intervals 3.1.1 Introduction 75 3.1.2 Method 75 3.1.3 Results 76 3.1.4 Discussion 77 3.1.5 Conclusion 77 3.2 Current practice-Retrospective audit on Telephone follow up 3.2.1 Introduction 78 3.2.2 Method 78 3.2.3 Results 79 3.2.4 Discussion 80 3.2.5 Conclusion 82 PART 4: RATIONALE AND OBJECTIVES OF TIMES STUDY 4.1 Rationale for Mixed methodology 84 4.1.1 Meaning of Acceptability and Preferences 84 4.1.2 A Brief History of Mixed Methodology 85 4.1.3 Definition 85 4.1.4 Mixed methodology for the TIMES study 86 4.1.5 Mixing Quantitative and Qualitative studies 88 4.2 Qualitative and Quantitative aspects of this study 90 4.2.1 Rationale for RCT for shorter time intervals 90 4.2.2 Rational for RCT to assess follow up 91 4.2.3 Rationale for Qualitative study 91 4.3 Objectives of the study 93 4.3.1 Objectives of RCT 93 4.3.2 Objectives of Qualitative study 93 PART 5: RANDOMISED CONTROLLED TRIAL 5.1 Methodology 96 5.1.1 Study design 96 5.1.2 Subject Population 98 5.1.3 Sample size calculation 98 5.1.4 Subject Recruitment and Consent 98 5.1.5 Randomisation 99 5.1.6 Data Collection 99 5.1.7 Data Generation and analysis 100 5.1.8 Study monitoring 101 5.1.9 Ethical Considerations 101 5.2 Results of Quantitative study: Efficacy and Follow up 5.2.1 Introduction and overview 102 5.2.2 Study Population 102 5.2.3 Results 102 5.2.3.1 Baseline characteristics 102 5.2.3.2 Efficacy 103 5.2.3.3 Secondary outcomes 104 5.2.3.4 Results on follow up 105 5.2.4 Assessment of non-participants 106 5.3 Discussion 107 5.3.1 The results in context 107 5.3.1.1 Efficacy of shorter time intervals 107 5.3.1.2 Follow up 110 5.3.2 Strengths and limitations of the study 112 5.3.2.1 Design and conduct of the trial 112 5.3.2.2 Intervention and Follow-up 116 PART 6: QUALITATIVE STUDY: IN-DEPTH INTERVIEWS 6.1 Research methodology for Qualitative study 119 6.1.1 Introduction 119 6.1.2 Justification for Qualitative methodology 119 6.1.3 Justification for In-depth interviews 120 6.1.4 Research Process 121 6.1.4.1 Developing the interview guide 121 6.1.4.2 Recruitment of interviewees 122 6.1.4.3 Conduct of the interviews 123 6.1.4.5 Characteristics of the researcher 124 6.1.4.6 Data analysis 125 6.1.5 Ethical considerations 126 6.2 Results of qualitative study 127 6.2.1 Participants characteristics 127 6.2.2 Attitudes towards abortions 127 6.2.2.1 General views of participants on abortions 127 6.2.2.2 Personal views of participants on Abortions 129 6.2.2.3 Views on cultural aspects of abortions 131 6.2.2.4 Men’s views on abortions 133 6.2.2.5 Personal views on repeat abortions 136 6.2.3 Process of decision making 136 6.2.3.1 Influence on decision making 136 6.2.3.2 Reasons involved in decision making 139 6.2.3.3 Personal reasons of the participants for having an abortion 139 6.2.4 Attitudes towards various methods of abortions 143 6.2.4.1 General views on preference for abortion methods 143 6.2.4.2 Influence on choice of type of abortion- surgical or medical 147 6.2.4.3 Reasons for preferring Medical abortions 148 6.2.4.4 Experience with previous abortion methods 151 6.2.5 Views on newer methods of medical abortions 151 6.2.5.1 Various routes 151 6.2.5.2 Same day vs Longer time intervals 153 6.2.5.3 Home management 156 6.2.5.4 Over the counter use 157 6.2.5.5 Perceptions of newer treatment regimens for medical Abortions 158 6.2.6 Views on very early abortions 159 6.2.6.1 Awareness about Ultrasonography 159 6.2.6.2 Determining Gestational Age on Ultrasound and its effect on women 159 6.2.6.3 Views on Ultrasonography images 160 6.2.6.4 Views on very early abortions 161 6.2.6.5 Views and Perceptions on complications of very early Abortions 163 6.2.7 Views on Follow up 164 6.2.7.1 Personal views on follow up 164 6.2.7.2 Timing of Follow up 167 6.2.7.3 Time taken to recover 167 6.2.7.4 Long term implications 169 6.2.8 Expectations about medical abortion 171 6.2.8.1 Expectations from health care 171 6.2.8.2 Views on consultation and approach of health care Professionals 172 6.2.9.
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • C:\Myfiles\Linda's Work\Houchens\WA 2-6
    1 2 This page intentionally left blank. 3 4 Draft Steroidogenesis DRP 110 May 2002 1 6.0 DEVELOPMENTAL STATUS OF THE ASSAY AND RECOMMENDATIONS 2 FOR PREVALIDATION STUDIES 3 4 6.1 Current Status 5 6 The endpoint included in the sectioned testes assay has been evaluated in other studies. 7 However, the protocol itself has not been validated. Pending a final decision on the study 8 design, the protocol would be ready to enter the prevalidation phase. 9 10 6.2 Recommendation for Optimization of the Sectioned Testis Assay Protocol 11 12 6.2.1 Testicular Preparation Issues 13 14 Optimization of the assay could be determined for the amount of testis actually needed to 15 obtain a given level of sensitivity. For example, a single testis from an adult SD rat weighs 16 approximately 1 g. If such a testis were quarter sectioned, then each section would weigh 17 approximately 250 mg, which is the weight of the sample generally described by investigators 18 who have used quartered sections of testis. However, no documentation was found that 19 demonstrates whether smaller sections would give similar results. Thus, it would be 20 advantageous to conduct a study that investigates whether the sensitivity of the preparation is 21 affected by the amount of testicular tissue used and, if so, if there is an optimal and/or threshold 22 amount to use. The weight of the sections to be tested could range from the customary amount 23 used, i.e., 250 mg, down to an amount of tissue that represents a practical minimum, e.g., 5 to 24 10 mg.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Cortisol, Pregnene and Pregnane Profiles in Normal and Dysmature Newborn Pony Andlighthorse Foals
    AN ABSTRACT OF THE THESIS OF Bernadette E. Voller for the degree of Master of Science in Animal Science presented on April 15, 1993. Title: Cortisol, Pregnene and Pregnane Profiles in Normal and Dysmature Newborn Pony andLighthorse Foals. Abstract approved: Redacted for Privacy In order to study normal and abnormalprogestin biosynthesis, 15 newborn lighthorse and pony foals(325 to 358 d gestation) were either givensynthetic ACTH (.2 IU/kg BW, i.v., n = 3), ACTH togetherwith a 3B- hydroxysteroid dehydrogenase blocker (trilostane) (10 mg/kg BW, p.o., n = 7), or no treatment (n = 5) at 4 h of age. Plasma samples were taken from birth through 96h of age and assayed for cortisolby radioimmunoassay, and for pregnenolone, 5-pregnene-36,20B-diol (P5BB), 5-pregnene- 38,20a-diol (P5Ba), progesterone, 5a-pregnane-38,20B-diol (5a-DHP-BB), 5a-pregnane-38,20a-diol (5a-DHP-Ba),38- hydroxy-5a-pregnan-20-one (38-0H-5a-DHP) and 20B-hydroxy- 4-pregnen-3-one (20B-P4) by gas chromatography/mass spectrometry. Preliminary comparisons demonstrated no significant differences in cortisol or progestin concentrations between normal foals given ACTH and ACTH/trilostane treatments and these groups werecombined for statistical purposes. In normal foals cortisol increased from birth (99.54 ± 7.44 ng/ml, mean ± SE) to maximum (124.18 ± 28.89 ng/ml) within 1 h of birth and rapidly declined, increasing again if treated with ACTH (129.04 ± 14.23 vs 24.11 ± 2.72 ng/ml at 6 h, for ACTH and normals, respectively)(P < .05); cortisol was below 11 ng/ml by 48 h.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Biology and Detection of Pregnanes During Late Gestation in the Mare
    University of Kentucky UKnowledge Theses and Dissertations--Veterinary Science Veterinary Science 2017 Biology and Detection of Pregnanes During Late Gestation in the Mare Michelle Arelia Ann Wynn University of Kentucky, [email protected] Digital Object Identifier: https://doi.org/10.13023/ETD.2017.209 Right click to open a feedback form in a new tab to let us know how this document benefits ou.y Recommended Citation Wynn, Michelle Arelia Ann, "Biology and Detection of Pregnanes During Late Gestation in the Mare" (2017). Theses and Dissertations--Veterinary Science. 28. https://uknowledge.uky.edu/gluck_etds/28 This Master's Thesis is brought to you for free and open access by the Veterinary Science at UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Veterinary Science by an authorized administrator of UKnowledge. For more information, please contact [email protected]. STUDENT AGREEMENT: I represent that my thesis or dissertation and abstract are my original work. Proper attribution has been given to all outside sources. I understand that I am solely responsible for obtaining any needed copyright permissions. I have obtained needed written permission statement(s) from the owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic distribution (if such use is not permitted by the fair use doctrine) which will be submitted to UKnowledge as Additional File. I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and royalty-free license to archive and make accessible my work in whole or in part in all forms of media, now or hereafter known.
    [Show full text]
  • Differential Effect of Trilostane on the Progestin Milieu in the Pregnant Mare W
    Differential effect of trilostane on the progestin milieu in the pregnant mare W. E. Schutzer, J. L. Kerby and D. W. Holtan lDeparlment of Animal Sciences, and 2College of Pharmacy, Oregon State University, Corvallis, OR 97331, USA Trilostane, a competitive inhibitor of 3\g=b\-hydroxysteroiddehydrogenase, was administered intravenously to pregnant mares (n = 3) between day 277 and day 282 of gestation to determine its effect on the progestin milieu. In addition, placental tissue from mares at mid-gestation (150\p=n-\300days) (n = 4) were exposed to either deuterium-labelled pregne- nolone alone or deuterium-labelled pregnenolone and trilostane to examine the effect of trilostane on placental metabolism of pregnenolone. Blood samples were collected from indwelling jugular catheters at frequent intervals for 48 h after infusion. Both plasma samples and incubation media were quantitatively analysed, after solid phase extraction and steroid derivitization, for concentrations of eight different progestin metabolites using gas chromatography and mass spectrometry. Trilostane infusion differentially affected the progestin milieu in vivo without inducing abortion. Forty-five minutes after infusion, maternal plasma concentrations of pregnenolone, 5-pregnene-3\g=b\,20\g=b\-diol,5\g=a\-pregnane\x=req-\ 3\g=b\,20\g=b\-dioland 3\g=b\-hydroxy-5\g=a\-pregnan-20-oneincreased (P < 0.05) and remained high for 37 h. Concentrations of 5\g=a\-pregnane-3,20-dione,20\g=a\-hydroxy-5\g=a\-pregnan-3-oneand 5\g=a\-pregnane-3\g=b\,20\g=a\-dioldecreased 15 min after infusion (P < 0.05), yet 1.5 h after infusion, concentrations had increased and remained high until 37 h after infusion.
    [Show full text]
  • Regulation of the Rate-Determining Step in the Steroidogenic Cascade in Rat Leydig Cells
    Regulation of the Rate-Determining Step in the Steroidogenic Cascade in Rat Leydig Cells Regulatie van de Snelheids-Bepalende Stap in de Steroldogene Cascade in Leydig Cellen van de Rat Proefschrift ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam op gezag van de Rector Magnificus Prof. Dr P. W.C. Akkermans M.A. en volgens besluit van het College voor Promoties. De openbare verdediging zal plaatsvinden op woensdag 30 oktober 1996 om 11,45 uur door Elisabeth Jacqueline Maria van Haren geboren te Vught omslag: 'Mitochondrial Mall' door Katinka van Haren Promotie-commissie Promotor Prof. dr. J.A. Grootegoed Overige leden: Prof. dr. H.J. Degenhart Prof. dr. F.H. de Jong Prof. dr. A.G.H. Smals Co-promotor Dr. F.F.G. Rommerts :::I~NDOCRINOLOGY ROTlfROAIt Dit proefschrift werd bewerkt binnen de Vakgroep Endocrinologie & Voortpianting van de Faculteit der Geneeskunde en Gezondheidswetenschappen, Erasmus Universiteit Rotterdam. Contents Abbreviations and Trivial Names 7 Chapter 1 Introduction 9 1.1. Testicular steroid production 10 1.1.1. Leydig cells 10 1.1.2. The steroidogenic cascade 11 1.1.3. Rate-determining step in the steroidogenic cascade 16 1.1.4. Measurement of Leydig cell steroid production 18 1.2. Regulation of the steroidogenic cascade by LH 19 1.2.1. Short-tenn effects of LH 19 1.2.2. Long-tenn effects of LH 23 1.2.3. Modulation of LH action by local factors 24 1.3. Aim and scope of this thesis 26 Chapter 2 Sterol Carrier Protein (Non-Specific Lipid Transfer Protein) is Localized in Membranous Fractions
    [Show full text]
  • Dynamics of Normal Ovarian Follicular Development
    GENE EXPRESSION PROFILING OF BOVINE OVARIAN FOLLICULAR SELECTION A Dissertation Presented to The Faculty of the Graduate School University of Missouri-Columbia In Partial Fulfillment Of the Requirement for the Degree Doctor of Philosophy By Zhilin Liu Dr. Eric Antoniou, Dissertation Supervisor December 2006 The undersigned, appointed by the Dean of the Graduate School, have examined the dissertation entitled Gene expression profiling of Bovine Ovarian Follicular Selection Presented by Zhilin Liu a candidate for the degree of Doctor of Philosophy and hereby certify that in their opinion it is worthy of acceptance. _______________________________________ Dr. Eric Antoniou _______________________________________ Dr. H. Allen Garverick _______________________________________ Dr. Gary S. Johnson _______________________________________ Dr. William R. Lamberson _______________________________________ Dr. Michael Smith _______________________________________ Dr. Jerry Taylor ACKNOWLEDGEMENTS First I would like to take this opportunity to express my appreciation to my advisor, Dr. Eric Antoniou, for letting me pursue my doctoral degree under his guidance. For more than six years, he has provided an encouraging environment for me to learn and grow in the research. His consistent guidance and cordial advice on my research have been invaluable. Many thanks to my committee members: Dr. Allen H. Garverick, Dr. William R. Lamberson, Dr. Gary S. Johnson, Dr. Michael Smith and Dr. Jerry Taylor for their encouragement and mentoring throughout my course of studies and completion of this work. Very special thanks to Dr. H. Allen Garverick and his lab member Malinda N. Burkhart, Dr. Robert S. Youngquist, Dr. Jerry Taylor and his lab member Erin M. Sellner, for their direct collaborations on different parts of this dissertation research.
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]